Analysis of advancer NSCLC patients with prolonged progression-free survival after EGFR tyrosine kinase therapy

Abstract

Authors provide analysis of the non small cell lung cancer group of patients having had progression free survival time longer than 180 days. The only significant factor associated with therapeutic benefit were mutations of EGFR genes.

Patients were treated with either erlotinib or gefitinib.

Keywords

• EGFR tyrose kinase inhibiotr therapy
• advanced NSCLC
• EGFR mutation
• KRAS mutation